Natixis Advisors, L.P.
- SEC CIK
- 0001018331
- Latest filing
- Aug 14, 2026
CRSP holding history
CRISPR Therapeutics AG in every 13F filed by Natixis Advisors, L.P., including the quarters it was sold out or no filing was made. Changes compare share counts with the previous calendar quarter.
CRSP overviewAll 13F holders of CRSPFull Q2 2026 holdings
- Shares (Q4 2024)
- 0
- Sold out in Q4 2024
- Value
- $0
- % of portfolio
- 0.0%
- Quarters held
- 14
- Since Q2 2021
| Quarter | Shares | Value | % of portfolio | Share change | Action | All holders |
|---|---|---|---|---|---|---|
| Q4 2024 | 0 | $0 | 0.0% | −10,042−100.0% | Sold out | Holders |
| Q3 2024 | 10,042 | $472.0K | <0.1% | −864−7.9% | Reduced | Holders |
| Q2 2024 | 10,906 | $589.0K | <0.1% | +400+3.8% | Added | Holders |
| Q1 2024 | 10,506 | $716.0K | <0.1% | +365+3.6% | Added | Holders |
| Q4 2023 | 10,141 | $634.0K | <0.1% | −1,566−13.4% | Reduced | Holders |
| Q3 2023 | 11,707 | $531.0K | <0.1% | −308−2.6% | Reduced | Holders |
| Q2 2023 | 12,015 | $675.0K | <0.1% | −434−3.5% | Reduced | Holders |
| Q1 2023 | 12,449 | $563.0K | <0.1% | −306−2.4% | Reduced | Holders |
| Q4 2022 | 12,755 | $519.0K | <0.1% | −2,702−17.5% | Reduced | Holders |
| Q3 2022 | 15,457 | $1.01M | <0.1% | −1,676−9.8% | Reduced | Holders |
| Q2 2022 | 17,133 | $1.04M | <0.1% | −402−2.3% | Reduced | Holders |
| Q1 2022 | 17,535 | $1.10M | <0.1% | +83+0.5% | Added | Holders |
| Q4 2021 | 17,452 | $1.32M | <0.1% | −1,676−8.8% | Reduced | Holders |
| Q3 2021 | 19,128 | $2.14M | <0.1% | +9,104+90.8% | Added | Holders |
| Q2 2021 | 10,024 | $1.62M | <0.1% | +10,024 | New | Holders |